We are interested in multiple alliance structures that can build upon and expand on the Illuminox™ platform to advance treatment options for patients with cancer.
Therapies or devices that can be incorporated into our Illuminox™ platform and tumor microenvironment.
Therapies that can be developed in combination with our lead drug, ASP-1929.
Companies that can assist in the clinical development and commercialization of our lead product, ASP-1929, in specific geographic territories.
Centers of excellence that can participate in the clinical development and enrollment of our clinical trials for investigational products developed on the Illuminox™ platform.